JV-1-40, Antagonist of GHRH receptor, CAS No.rp174396, Antagonist of GHRH receptor

CAS: rp174396 Cat. No.: rp174396

GRADE & PURITY Moligand™

Specifications

Product Name

JV-1-40, Antagonist of GHRH receptor, CAS No.rp174396

Grade

Moligand™

Specifications & Purity

Moligand™

Action Type

ANTAGONIST

Mechanism of action

Antagonist of GHRH receptor

CAS

rp174396

Molecule Type

Peptide

Product Line

Biological Products

Storage and Shipping

Storage

Room temperature

Associated Targets(Human)

GHRHR Tclin Growth hormone-releasing hormone receptor (0 Activities)

Discover Target: GHRHR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Genetic information

• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

No tested application protocols are provided for this item in the catalog listing.

General workflow suggestions for small-molecule ligands (informational):

• Stock preparation: Dissolve in dry DMSO to a convenient concentration (e.g., 10–50 mM), confirm clarity, and aliquot to minimize freeze–thaw.
• Biochemical assays: Titrate compound across a log-scale concentration range; maintain consistent final DMSO across wells/conditions. Include vehicle controls.
• Cell-based assays: Verify cytotoxicity/viability impacts of vehicle and compound across relevant exposure times. Keep final DMSO typically ≤0.1–0.5% v/v unless validated otherwise.
• Data quality: Include replicates, counter-screens for interference, and orthogonal confirmation where possible.

Item-specific recommended dilutions, positive controls, or platform-specific parameters: Not specified for this item; refer to CoA/Spec Sheet or your internal SOPs.

Biological Roles

Specific biological targets, pathways, or mechanism-of-action data for JV-1-40 are not provided in the catalog entry. The compound is supplied for research use only.

General considerations for library ligands:

• Screening role: Such compounds are commonly used to probe biochemical pathways, validate targets, or seed structure–activity relationship (SAR) studies.
• Profiling strategy: Combine primary assays with orthogonal readouts (e.g., biophysical binding, thermal shift, SPR, BLI) to corroborate activity and reduce false positives.
• Off-target awareness: Early counter-screens against frequent hitters or assay-interfering motifs (fluorescence quenchers/emitters, redox cyclers, detergents) help triage artifacts.
• Physicochemical profiling: Where possible, measure solubility, pKa, logD, and stability in relevant matrices (buffer, cell media) to contextualize hit quality.

Documentation note:

• Any claimed biological role or potency should be established within your laboratory or sourced from peer-reviewed literature specifically about JV-1-40. In the absence of such data here, no biological role is asserted.

Buffer Applications

This product is a research ligand and is not itself a buffering agent. No item-specific buffer system or pH data are provided.

Practical guidance (general):

• For aqueous assay use, dissolve first in a suitable organic stock solvent (commonly DMSO), then dilute into the target buffer (e.g., PBS, HEPES, Tris) maintaining a final organic content typically ≤0.1–1% v/v.
• If precipitation occurs on dilution, consider: (a) reducing dilution factor; (b) modestly increasing organic cosolvent; (c) adjusting buffer pH to favor ionization of acidic/basic groups; or (d) preparing a salt form when appropriate.
• For protein-binding or biophysical assays, match buffer composition (ionic strength, pH) to the primary assay protocol and include consistent cosolvent controls.

Item-specific buffer recipes, pKa, and pH ranges: Not specified for this item; refer to CoA/Spec Sheet if available.

Green Alternatives

In the absence of item-specific solvent or process requirements, consider greener practices for solution preparation and screening workflows.

Greener solvent choices for stock and assay solutions (general):

• Prefer ethanol or isopropanol as co-solvents when compatible with the assay and compound solubility, potentially reducing reliance on higher-toxicity dipolar aprotics.
• Replace high-boiling dipolar aprotics (e.g., NMP, DMF) with propylene carbonate or Cyrene where feasible; verify solubility and assay compatibility.

Illustrative comparison (general, literature):

• DMSO: Widely compatible; moderate environmental footprint; high solvency.
• Ethanol: Renewable routes available; low toxicity; may denature proteins at higher %.
• Propylene carbonate: Low volatility; greener profile; viscosity can complicate liquid handling.
• Cyrene (dihydrolevoglucosenone): Bio-based; strong solvent power; compatibility varies.

Operational green tips:

• Minimize DMSO percentages in assays by preparing higher-concentration master stocks and diluting immediately before use.
• Use smaller aliquots to prevent repeated freeze–thaw cycles, reducing waste from degraded stock.
• Implement microplate-based solubility pre-screens to avoid excess solvent consumption.

Note: Always confirm that any alternative solvent system maintains assay performance and compound integrity. No item-specific green constraints are provided for JV-1-40.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation guidance is provided for this product. JV-1-40 is supplied strictly for research use only.

General notes for researchers working toward pre-formulation studies (informational, non-clinical):

• Establish fundamental properties (solubility vs pH, stability in biorelevant media) and evaluate salt formation potential before any advanced formulation exploration.
• Early assessment of hygroscopicity and polymorphism (PXRD/DSC/TGA) can be informative if scale-up or long-term storage is anticipated for extended research programs.

Item-specific regulatory/designation information (USP/EP/JP monographs, residual solvent class limits, elemental impurities controls): Not specified for this item; refer to CoA/Spec Sheet. No clinical or therapeutic claims are made or implied.

Physical Properties

Item-specific physicochemical data are not provided in the catalog listing and should be consulted on the CoA/Spec Sheet.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not applicable or rarely defined for library solids; Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable for solids; Not specified for this item; refer to CoA/Spec Sheet.
• pKa / logP (literature/computed, if available): Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/general):

• For small-molecule ligands of unknown properties, begin solubility screening with dry DMSO (analytical or anhydrous grade), followed by mixed aqueous vehicles (e.g., DMSO to 0.1–1% v/v final in assay) or co-solvent systems (DMSO:water, DMSO:PBS, DMSO:buffered saline).
• If basic or acidic functional groups are suspected, create salt stocks (e.g., HCl or TFA salts for bases; Na+ or triethylammonium salts for acids) to enhance aqueous compatibility.
• Evaluate stability in light and air; some heteroaromatics or redox-active motifs can degrade under UV or oxidative conditions. Protect from light as a precaution until specific data are available.

Quality & Grades

This product is supplied as Moligand™ grade, denoting a research ligand suitable for screening, target validation, and SAR exploration.

What Moligand™ typically implies (general description):

• Emphasis on identity confirmation and purity suitable for biochemical/biophysical screening campaigns.
• Packaging conducive to rapid dissolution in common screening solvents (e.g., DMSO) and minimizing adsorption/contamination.
• Batch documentation: CoA/Spec Sheet typically includes identity confirmation (e.g., LC–MS/HRMS) and purity metrics. For acceptance limits and exact methods, see the CoA/Spec Sheet.

Item-specific notes:

• Purity/assay, residual solvents, water content, stabilizers, and detailed chromatographic traces: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance and lot-to-lot acceptance criteria: Not specified for this item; refer to CoA/Spec Sheet.

Practical guidance for users:

• For screening, prepare DMSO stocks at a convenient concentration (e.g., 10–50 mM) if solubility permits. Filter sterilization is generally unnecessary unless required by your workflow; if needed, use low-binding PVDF or PTFE filters.
• Upon receipt of a new lot, verify identity/purity in-house against your acceptance criteria (e.g., LC–MS purity ≥95% at 210–254 nm or as your assay demands) before use in high-value studies.

Reaction & Applications

This product is positioned as a Moligand™ research ligand rather than a general synthetic reagent. No manufacturer reaction use-cases are provided. Accordingly, synthetic reaction applications are not typically the primary use. Instead, focus on screening and discovery contexts.

Typical research applications for Moligand-type compounds (general):

• Biochemical/biophysical assays: enzyme modulation, receptor binding, or probe development studies (mechanism-agnostic at this stage).
• Cell-based assays: phenotypic screening to explore pathways and prioritize chemical matter. Maintain DMSO ≤0.1–0.5% v/v unless otherwise validated.
• Orthogonal profiling: check for assay interference (e.g., redox activity, fluorescence, detergent-like behavior) by using counter-screens and PAINS filters as appropriate.

Practical tips:

• Stock preparation: Prepare concentrated DMSO stock (e.g., 10–50 mM) as solubility allows; vortex, brief sonication, and gentle warming (≤40 °C) can aid dissolution.
• Adsorption losses: Use low-binding tubes/plates for low-concentration work; pre-rinse with solvent if carryover is a concern.
• Stability checks: Assess freeze–thaw tolerance and light sensitivity with a small aliquot before committing the full lot.

Note: If you intend to use JV-1-40 as a synthetic intermediate, validate reactivity independently; no item-specific reactivity data are provided.

Reaction Conditions

No item-specific reaction conditions are provided, and JV-1-40 is not offered as a reagent for a specific named transformation.

General guidance if derivatization is pursued (informational):

• Solvent and temperature: Select conditions based on confirmed functional groups after structural disclosure/verification. Start with mild conditions and incrementally optimize.
• Workup and isolation: For small-scale medicinal chemistry, favor parallel purification (flash chromatography or preparative LC) with UV/ELSD monitoring compatible with the compound’s chromophores/volatility.
• Stability: Screen for acid/base sensitivity and redox lability with spot tests before committing to multi-hour reactions.

Expected yields, catalysts, and time scales (literature general): Highly dependent on the specific transformation and are not defined for this item. Always consult primary literature once the structure and target transformations are known.

Safety & Handling

Hazard classification for this specific item is not provided in the catalog entry. Always consult the product SDS for authoritative safety data.

• Signal word: Not specified for this item; refer to SDS.
• GHS pictograms/classification: Not specified for this item; refer to SDS.
• H-statements: Not specified for this item; refer to SDS.

General laboratory precautions (good practice):

• Wear appropriate PPE: lab coat, safety glasses, and suitable chemical-resistant gloves.
• Work in a chemical fume hood to avoid inhalation exposure, especially during weighing, dissolution in volatile solvents, or sonication that could aerosolize solutions.
• Avoid skin/eye contact and ingestion; prevent dust formation with powders.
• Storage incompatibilities: Until specific data are available, segregate from strong oxidizers and acids/bases that could promote decomposition; avoid prolonged light exposure.
• First aid (overview; see SDS for details):
  • Eye/skin contact: Rinse with water for 15 minutes; remove contaminated clothing; seek medical guidance.
  • Inhalation: Move to fresh air; monitor breathing; seek medical attention if symptoms persist.
  • Ingestion: Rinse mouth; do not induce vomiting; obtain medical assistance.

Waste and spill response:

• Capture spills with inert absorbent; dispose of according to institutional hazardous waste protocols. For unknown hazard profiles, treat as potentially harmful and non-volatile organic waste.

Solvent Selection

Item-specific solvent compatibility is not listed. Use the following decision framework to identify a suitable solvent system for JV-1-40 in research workflows.

• Primary stock solvent (general):
  • Dry DMSO (analytical or anhydrous) is the default for Moligand-type small molecules due to broad solvating power and assay compatibility at ≤0.1–1% v/v.
• Secondary solvents/co-solvents (general):
  • DMF, NMP: high polarity alternatives if DMSO is unsuitable for the assay surface or detection method.
  • Alcohols (MeOH, EtOH, i-PrOH): useful as co-solvents (≤10–20% v/v) to aid aqueous dissolution; verify assay tolerance.
  • Aqueous buffers: If ionizable groups are suspected, adjust pH to favor the soluble ionization state (e.g., pH 2–4 for basic amines; pH 8–10 for acids), keeping ionic strength compatible with the assay.
• Miscibility profile (general knowledge): DMSO is fully miscible with water and many organic solvents, facilitating serial dilutions.

Comparison snapshot (general):

• DMSO: highest solvating power; can affect certain enzyme activities/spectra at >1% v/v.
• DMF/NMP: strong solvators; consider cytotoxicity and extractables with plastics.
• MeOH/EtOH: lower toxicity footprint; may impact protein stability.

Tip: Perform a rapid 6–8 point solvent screen at room temperature, checking for clarity, color change, and stability over 24–48 h.

Storage & Reconstitution

Storage conditions provided by the catalog: Room temperature.

• Storage: Store at room temperature as indicated. In the absence of item-specific sensitivity data, keep tightly closed in the original container, in a dry place, protected from prolonged light exposure.
• Shipping: Not specified for this item; refer to CoA/Spec Sheet.
• Stability: Not specified for this item; refer to CoA/Spec Sheet. As a precaution, minimize exposure to moisture and air.

Reconstitution (general guidance):

• Prepare initial DMSO stock solutions (e.g., 10–50 mM) if compatible; confirm full dissolution by visual inspection and, when critical, by analytical check (LC).
• For aqueous working solutions, dilute the organic stock into buffer/media with thorough mixing; maintain consistent final organic content across samples.
• Aliquoting: Create single-use aliquots to avoid repeated freeze–thaw if you choose to store solutions refrigerated or frozen. Label aliquots with concentration, solvent, date, and lot.

Research use statement: For research use only. Not for human or veterinary use.

Any item-specific shelf life, stabilizers, or special handling precautions: Not specified for this item; refer to CoA/Spec Sheet.

Structure & Identity

Brief overview: JV-1-40 is offered as a Moligand™ research ligand from our small-molecule/compound library collection. Detailed structural identifiers are not provided in the catalog entry and should be taken from the accompanying CoA/Spec Sheet when available.

• SKU: rp174396
• Product name: JV-1-40 (Moligand™ grade)
• Category: Small molecules and compound libraries (全部 / 可售 / 小分子和化合物库)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChI / InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• CAS: rp174396 (catalog placeholder; not a registry number)

Structural features (general guidance for users):

• When available, review the 2D structure to identify key functional groups (e.g., heteroaromatics, amide/urea motifs, basic amines, halogens) that can influence solubility, ionization, and assay behavior.
• Check for chiral centers or restricted geometries (E/Z, atropisomers), which may affect biological profiling and interpretation of SAR.
• If multiple tautomers or ionization states are plausible, prepare stocks accordingly (e.g., base/acid addition salts) to improve solution stability and assay reproducibility.

Documentation reminder:

• For unambiguous identity confirmation in your lab, verify by orthogonal methods where possible (e.g., LC–MS, HRMS, 1H/13C NMR), using the CoA-supplied reference values as acceptance criteria.

Synthetic Utility

JV-1-40 is provided as a Moligand™ research ligand intended primarily for screening and discovery rather than as a general-purpose synthetic reagent or building block.

Implications for synthetic use (general):

• Unknown functional group content: Without a disclosed structure, assumptions about reactivity, protecting-group compatibility, or stability cannot be made. Validate any planned transformations by small-scale pilot experiments.
• Derivatization strategy: If using as a starting point for SAR, obtain or elucidate the structure and identify modifiable positions (e.g., aryl halides for cross-coupling, amines/acids for amide formation) before route design.
• Analytical control: Employ LC–MS, NMR, and, where needed, HRMS to track conversions; establish impurity profiles for any derivatives prepared in-house.

Item-specific reactive handles, named-reaction suitability, and protecting-group strategies: Not specified for this item; refer to CoA/Spec Sheet or internal structure documentation.

Target Specificity

Target, binding site/epitope, species reactivity, and any selectivity data for JV-1-40 are not provided in the product entry.

• Antigen/target name: Not specified for this item; refer to CoA/Spec Sheet.
• Assay-validated potency/selectivity metrics: Not specified for this item; refer to CoA/Spec Sheet.

Guidance for researchers (general):

• Use orthogonal methods (biochemical assays, SPR/BLI, DSF, CETSA) to confirm binding/engagement and to deconvolute mechanism(s) of action.
• Benchmark against internal standards and include negative controls to rule out assay interference or non-specific effects.

No claims are made regarding the biological target or selectivity profile of JV-1-40.